Sodium Benzoate Added to Antipsychotics for Resistant Schizophrenia
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether adding a supplement called sodium benzoate to your current antipsychotic medication can improve symptoms in schizophrenia that hasn't responded well to standard treatments. Researchers will measure brain chemistry changes and symptom improvement over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with schizophrenia or schizoaffective disorder (a related condition with mood changes)
- Your symptoms have not improved despite trying at least 2 different antipsychotic medications at adequate doses for at least 6 weeks each
- You have had persistent symptoms for at least 6 months without getting significantly better
- You do not have other medical conditions, neurological disease, or substance use disorder
- You can safely have an MRI scan (brain imaging) and do not have metal implants that prevent it
- You are willing to have blood samples taken to measure brain chemistry
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This study tests a new treatment that may help with thinking and memory problems in people with schizophrenia. It is for people whose schizophrenia symptoms are stable and who are already on a steady medication.
This trial tests an experimental combination treatment that targets two different brain receptors (sigma-1 and NMDA) to see if it can improve symptoms in people with schizophrenia that hasn't responded well to standard antipsychotics.
This trial tests whether combining an NMDA “signal-supporting” treatment with an anti-inflammatory medicine can reduce symptoms in people with schizophrenia who don’t respond well to usual antipsychotic drugs. If you’ve tried at least two antipsychotics and you’re still symptomatic, this study may be worth screening for.
This study tests whether a medication that boosts brain NMDA receptors can improve negative symptoms in schizophrenia, and looks at differences between men and women. It is for people with stable schizophrenia who still have mostly flat mood or low motivation.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.